RESUMO
Non-steroidal anti-inflammatory drugs are often used analgetics in dentistry because of their analgetic and anti-inflammatory effects. Oral health care providers should know their interactions and side-effects meticulously. The automatic prescription of another analgetic just to avoid the side-affects is not always an option, since then the specific properties of NSAID's are missed. A correct patient information, specific medical controls, a combination with other medication or other measures may providefor a safe use of NSAID's. In case of healthy patients younger than 70 years of age and a medication time less than two weeks seldom specific measures are indicated.
Assuntos
Analgesia/métodos , Anti-Inflamatórios não Esteroides/efeitos adversos , Anti-Inflamatórios não Esteroides/uso terapêutico , Dor Facial/tratamento farmacológico , Fatores Etários , Interações Medicamentosas , Humanos , Fatores de TempoRESUMO
A major outbreak of dengue hemorrhagic fever (DHF) affected more than 10,000 people in Delhi and neighboring areas in 1996. The outbreak started in September, peaked in October to November and lasted till early December. The clinical and laboratory data of 515 adult patients admitted to Lok Nayak Hospital, New Delhi were reviewed. Fever (100%), myalgias and malaise (96%), abdominal pain (10.2%) and vomiting (8.7%) were the prominent presenting features. Hemorrhagic manifestations were seen in all patients- a positive tourniquet test (21.2%), scattered petechial rash (23.07%), confluent rash (2.7%), epistaxis (38.4%), gum bleeds (28.06%) and hematemesis (22.86%) being the major bleeding manifestations. Hepatomegaly was observed in 96% of the patients. Laboratory investigations revealed thrombocytopenia, hemoconcentration and leukopenia. Serological confirmation with a microcapture ELISA technic was done in 143/515 patients. The mortality rate was 6.6% and, multiple bleeding manifestations, severe thrombocytopenia, hypoproteinemia and dengue shock syndrome (DSS) were associated with a higher mortality.
Assuntos
Surtos de Doenças , Dengue Grave/epidemiologia , Adolescente , Adulto , Idoso , Criança , Feminino , Humanos , Índia/epidemiologia , Masculino , Pessoa de Meia-Idade , Estações do Ano , Dengue Grave/mortalidade , Dengue Grave/fisiopatologia , População UrbanaRESUMO
Cough is an important side effect of Angiotensin Converting Enzyme Inhibitor (ACEI) therapy. The incidence of cough was investigated in a prospective 8 week study in 250 hypertensive patients receiving ACEI alone or in combination with other agents. Enalapril (5-20 mg/day), Lisinopril (5-20 mg/day), Captopril (25-75 mg/day) or Ramipril (5-15 mg/day) was prescribed to patients, who were followed up at weekly visits. Cough developed in 73 of the 250 patients i.e. an incidence of 29.2%. Females had a higher incidence of cough as compared to males--37.9% versus 15.5% (p < 0.001) and there was no significant difference in the cough incidence in the various age groups. A dry, non-productive cough developed in all patients within 4 weeks of ACEI initiation. Increased nocturnal intensity of cough was reported by 79.4% patients. Cough incidence was 34.4%, 24.3% and 18.1% in patients on Enalapril, Ramipril and Lisinopril, respectively. Cough was not dose related and was not related to smoking. There was no statistically significant difference among patients on ACEI alone or in combination with beta blockers, calcium channel blockers or diuretics. Of the 18 patients with ACEI induced cough who received Indomethacin, 50 mg bid, 8 reported complete cure and cough was reduced in intensity in the remaining ten.
Assuntos
Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Tosse/induzido quimicamente , Tosse/epidemiologia , Hipertensão/tratamento farmacológico , Adulto , Idoso , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Captopril/efeitos adversos , Captopril/uso terapêutico , Tosse/tratamento farmacológico , Enalapril/efeitos adversos , Enalapril/uso terapêutico , Feminino , Seguimentos , Humanos , Incidência , Índia/epidemiologia , Indometacina/administração & dosagem , Lisinopril/efeitos adversos , Lisinopril/uso terapêutico , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Ramipril/efeitos adversos , Ramipril/uso terapêutico , Medição de RiscoRESUMO
The Senior-Loken syndrome, also called Hereditary Renal Retinal Dystrophy is a rare disorder that combines a juvenile nephronophthisis-like disease with tapetoretinal degeneration. We are reporting a family in which two, possibly three siblings are affected by this disorder. In addition to these two documented components of the disease, our patients also have unusual manifestations: short stature; skeletal abnormalities in the form of kyphoscoliosis, short metacarpals; and cutis laxa-unreported so far.